| Net loss | |
| Accrued interest expense | 6.34M |
| Amortization of debt issuance costs | |
| Depreciation and amortization | 10.84M |
| Impairment loss on intangible assets and equipment | |
| Provision for bad debts | 96K |
| Net impairment loss on marketable securities | |
| Inventory provision | 2.58M |
| Share-based compensation expense | 3.44M |
| Excess tax benefits from equity based compensation | |
| Non-cash income tax expense (benefit) | -735K |
| Accounts receivable | 9.88M |
| Inventories | 3.76M |
| Prepaid expenses and other assets | -6.19M |
| Accounts payable | -7.08M |
| Accrued expenses, income taxes, and other | |
| Net cash provided by (used in) operating activities | 51K |
| Purchases of property and equipment | -875K |
| Purchases of intangible assets | -2.09M |
| Purchases of securities | |
| Securities maturities/sales | |
| Net cash provided by investing activities | 6.19M |
| Proceeds from the issuance of short-term debt, net of issuance costs | |
| Principal payments under capital lease obligations | -722K |
| Proceeds from stock option exercises net of taxes paid on vested restricted stock units | |
| Excess tax benefits from equity based compensation | |
| Deposit of restricted funds | |
| Net cash used in financing activities | -1.49M |
| Effect of exchange rates on cash and cash equivalents | -147K |
| Net increase (decrease) in cash and cash equivalents | 4.6M |
| Cash and cash equivalents, beginning of period | 12.57M |
| Cash and cash equivalents, end of period | 17.17M |
| Interest | |
| Income taxes | |
| Marketable equity securities received in settlement of note receivable | |
| Accrued debt issuance costs | |